Nov. 4 Company Quick Takes: FDA approves RedHill’s antibiotic; plus NiKang, Revolution-Amgen, Aveo and Tmunity-Oncora

RedHill gets FDA approval for antibiotic
FDA approved Talicia from RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) to treat Helicobacter pylori infection in adults. RedHill plans to launch the fixed-dose combination of rifabutin, amoxicillin and omeprazole in 1Q20.

Cancer company NiKang launches with Li at its helm
NiKang Therapeutics Inc. emerged from stealth Monday with the hiring of Peter Li as CEO. He was co-founder, chairman and CEO of Turning Point Therapeutics Inc. (NASDAQ:TPTX). NiKang is developing small molecules using a target structure biology-based approach to drug discovery. ...